The overarching goal of this project is to examine the effect of combining theta burst
stimulation (TBS) and N-acetylcysteine (NAC) on cocaine craving and brain response to cocaine images. Participants (N=96) will undergo a baseline MRI visit to assess craving and brain function, then be randomized to one of four SHAM / Placebo-controlled TBS / NAC treatment conditions. Following 3-days of medication (NAC or Placebo), return to the lab for a second MRI visit where brain function will be assess immediately before and after TBS or SHAM stimulation. Participants will be contacted via phone over the following 3-weeks to assess mood and craving.
Nicotine addiction is a chronic, relapsing brain disorder and although it is the leading cause of preventable premature death in the US, ~20% of adults smoke and among those that try to quit, the majority relapse.Research suggest that nicotine addiction disrupts the working in the brain involved in motivation and reward. The overarching goal of this proposal is to utilize clinical neuroscience to investigate the effects of Mindfulness Oriented Recovery Enhancement (MORE) on modifying behavior to help treat nicotine addiction.
The broad objective of this proposal is to use fMRI methods to conduct preliminary investigation of the effects of Clavulanic Acid on neurocognition and smoking withdrawal in abstinent cigarette smokers. This project will involve collecting data from a total of approximately 40 adult smokers.
MUSC is recruiting adult cigarette smokers (18 to 65) who are interested in participating in a research study examining the effects of brain stimulation on neural activity and behavior. This study consists of 4 visits over the course of 2-3 weeks. Qualified individuals will be compensated for participation.
This study is investigating the effects of combining 2 medications, Varenicline (commonly known as Chantix®) and N-acetylcysteine, on smoking behavior in daily cigarette smokers who are interested in quitting smoking. The study consists of 10 visits over 6 weeks. Compensation is available for those that qualify. Smokers must be between the ages of 18 and 55.
Cigarette smoking is the leading preventable cause of death and disability in the U.S. and individuals with elevated depression symptoms or clinically diagnosed major depressive disorder (MDD) smoke at significantly higher rates than non-depressed individuals. Elevated negative affect and affective dysregulated emotional control may contribute to greater smoking among individuals with MDD. The proposed research will shed new light on the neural mechanisms that govern associations between depression and smoking. Despite known and costly associations between these factors, little is known regarding their co-occurrence and such information will provide a foundation for the development of novel and more effective interventions. We are recruiting adult smokers and nonsmokers, and individuals with or without depression, ages 18 and older to participate.